Opinion|Videos|August 5, 2024
Dr Dempsey Shares Impact of CDK4/6 Inhibitor Medication Costs on Breast Cancer Care & Needs for Adoption of Cost Containment Strategies
Dr. Dempsey discusses how CDK4/6 Inhibitors have impacted medication costs for breast cancer care, and the importance of implementing cost containment strategies to alleviate the situation.
Advertisement
Video content above is prompted by the following question(s):
- How does the use of CDK4/6 inhibitors in this space contribute to the total cost of care for breast cancer, and what cost containment strategies can we consider adopting?
Advertisement
Related to this article
A meta-analysis of HELIOS-B and CARDIO-TTRansform found gene silencers reduced death and CV events, driven by patients not taking stabilizers.
ApoB more directly reflects atherogenic particle burden than LDL-C, but missing outcome trials and assay variability still limit its routine use.
An analysis finds distinct adverse event reporting patterns across immunosuppressive regimens, highlighting the need for tailored safety monitoring.
On National Latinx AIDS Awareness Day, experts outline HIV prevention gaps in Hispanic communities and how payers can ease PrEP access.
In states that covered obesity-labeled GLP-1 RAs, total GLP-1 RA use rose less than obesity-labeled use alone, suggesting possible substitution.
HR 1 brings Medicaid work requirements and narrower immigrant eligibility by January 2027, and CBO projects 10 million more uninsured by 2034.
CMS ends ACA subsidies for 189,000 enrollees with duplicate Medicare, Medicaid, or CHIP coverage or listed as deceased, with a 30-day dispute window.
Sjögren disease involves far more than dry eyes and mouth, and variable symptoms plus multispecialty testing delay diagnosis, says Steven Carsons, MD.
Advertisement
Advertisement
Trending on AJMC
1
ACA Subsidies End for 189,000 Duplicate or Deceased Enrollees
2
Coroner Reports Pennsylvania's Sixth Measles-Associated Death
3
5 Things to Know About the One Big Beautiful Bill Act
4
Understanding the Potential Risks of Prescription Drug Affordability Boards and Upper Payment Limits
5